NEW YORK — Cancer drug developer HiberCell said on Monday that it has acquired Genuity Science, a provider of contract genomics and artificial intelligence-driven data sourcing and analytics services for drug development, in an all-stock transaction.
Under the terms of the deal, Boston-based Genuity Science — formerly known as WuXi NextCode — and its Irish and Icelandic subsidiaries will become a wholly-owned subsidiary of HiberCell.
HiberCell said it will gain Genuity's human genome analytics technology and computational platform, along with high-quality genomic, multiomic, and deeply characterized phenotype datasets in cancer as well as cardiometabolic, autoimmune, and neurological disorders. It will also pick up Genuity's roughly $100 million cash position and existing partnerships with Ionis and AbbVie.
"Our therapeutic programs have been identified through mechanistic insight into the role of the adaptive stress phenotype in cancer patients," Alan Rigby, HiberCell's cofounder and CEO, said in a statement. "Genuity's [artificial intelligence/machine learning] platform, which has successfully identified and validated novel molecular pathways in disease initiation and progression, is well positioned to further our understanding of the stress phenotype and its role in cancer progression."
Additional terms of the acquisition were not disclosed.
Earlier this year, New York City-based HiberCell partnered with Biodesix on the development of a companion diagnostic for a cancer immunotherapy.